SRRK
SCHOLAR ROCK HOLDING CORP
1 day chart
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company that is focused on the discovery and development of medicines for the treatment of serious diseases. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFβ1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. Its selective inhibitors of the activation of transforming growth factor-beta (TGFβ) for the treatment of fibrotic diseases. It is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFβ1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFβ1 presented by cells of the immune system.
Buy US stocks in Australia with $0 brokerage and trade SRRK today!
$357.87M
-
0.00%
192.19K
$7.46
$6.93
$7.00
$36.43
$4.33
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.